Benign Prostatic Hyperplasia
Conditions
Interventions
Population:Oral Finasteride daily 5mg for one year
Sponsors
The Chinese University of Hong Kong
Eligibility
Sex/Gender
Male
Age
50 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Ethnically Chinese men; 2. Aged 50-80 years; 3. Serum total PSA 4-10ng/mL with normal DRE at baseline; 4. Prostate size > 30ml on TRUS; 5. History of negative TRUSPB within last 6 months; 6. Informed consent signed by patient.
Exclusion criteria
Exclusion criteria: 1. Prior history of prostate cancer; 2. Patient taking 5-alpha reductase inhibitor (Finasteride or Dutasteride) within 12 months before recruitment; 3. Patient taking long term (>3 months) androgen or steroidal drugs within 12 months before recruitment; 4. Active urinary tract infection or prostatitis; 5. Bladder stone; 6. Patient on indwelling catheter or on intermittent catheterization of bladder.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change of p2PSA and PHI level after taking 5-alpha reductase inhibitor at 1 year; | — |
Countries
China
Contacts
Public ContactKa-Fung Peter CHIU
Division of Urology, Department of Surgery, Prince of Wales Hospital
Outcome results
None listed